Share on StockTwits

NeoGenomics (NYSE:NEO) announced its earnings results on Thursday. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01, AmericanBankingNews.com reports. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $19.84 million.

Several analysts have recently commented on the stock. Analysts at Dawson James initiated coverage on shares of NeoGenomics in a research note on Wednesday, May 14th. They set a “buy” rating and a $6.00 price target on the stock. On a related note, analysts at Longbow Research initiated coverage on shares of NeoGenomics in a research note on Monday, May 12th. They set a “buy” rating and a $6.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of NeoGenomics in a research note on Monday, May 12th. They set a “buy” rating and a $6.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $6.20.

Shares of NeoGenomics (NYSE:NEO) opened at 4.38 on Thursday. NeoGenomics has a one year low of $2.05 and a one year high of $4.82. The stock’s 50-day moving average is $3.56 and its 200-day moving average is $3.5. The company has a market cap of $217.6 million and a P/E ratio of 114.39.

NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.